Proteomics International Laboratories (PIQ) H2 2025 earnings summary

Executive summary

• Transitioned from R&D to commercialisation, launching PromarkerD for diabetic kidney disease in Australia and the USA, with first commercial sales and a CLIA-certified US lab established.

• PromarkerEndo for endometriosis and PromarkerEso for esophageal cancer advanced toward commercial launch, with PromarkerEndo targeting H2 CY25 and PromarkerEso completing validation.

• Raised $12 million in capital to accelerate commercial rollouts, expand operations, and strengthen leadership.

Financial highlights

• Revenue and other income decreased 2% to $3.51 million year-over-year, reflecting services, grants, and R&D tax incentives.

• Operational expenditure increased 16% to $11.7 million, driven by commercialisation efforts.

• Net loss before tax rose 26% to $8.15 million, including $1.4 million in non-cash items (depreciation and share-based payments).

• Cash reserves at year-end were $11.0 million, with a net operating cash outflow of $6.6 million.

• No dividends declared or paid for the year.

Outlook and guidance

• Focus on executing commercial launches for PromarkerD, PromarkerEndo, and PromarkerEso in Australia and the USA.

• Expansion of digital direct-to-consumer platforms and engagement with key opinion leaders to drive adoption.

• Ongoing R&D and commercialisation activities to be underpinned by analytical services revenue.